Free Trial

Bausch Health Companies (TSE:BHC) Stock Price Up 3% - Time to Buy?

Bausch Health Companies logo with Medical background

Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s stock price was up 3% during mid-day trading on Thursday . The company traded as high as C$11.67 and last traded at C$11.61. Approximately 76,142 shares traded hands during trading, a decline of 44% from the average daily volume of 137,096 shares. The stock had previously closed at C$11.27.

Analysts Set New Price Targets

Separately, Evercore ISI raised Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th.

Get Our Latest Analysis on Bausch Health Companies

Bausch Health Companies Price Performance

The firm's fifty day simple moving average is C$11.63 and its 200-day simple moving average is C$10.19. The firm has a market capitalization of C$4.18 billion, a PE ratio of -6.50, a PEG ratio of 0.21 and a beta of 0.77. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of 7,583.76.

Bausch Health Companies (TSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported C$1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of C$1.43 by C$0.10. The business had revenue of C$3.42 billion for the quarter, compared to analysts' expectations of C$3.36 billion. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. On average, research analysts forecast that Bausch Health Companies Inc. will post 5.5472637 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

See Also

Should You Invest $1,000 in Bausch Health Companies Right Now?

Before you consider Bausch Health Companies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.

While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Energy Vault’s 100% Stock Jump: CEO Discusses $350M Project in Australia in MarketBeat CEO Series

Energy Vault’s 100% Stock Jump: CEO Discusses $350M Project in Australia in MarketBeat CEO Series

Energy Vault's innovation in sustainable energy storage is gaining traction across the globe; could this $2 stock be a hidden gem for future growth?

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines